Pediatric Studies Delayed Mostly By FDA Red Tape, Companies Say
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA posts non-compliance letters and responses from three sponsors that failed to meet deadlines for submitting reports for trials of four drugs in children; more than 70 firms have had their deadlines extended.
You may also be interested in...
Pediatric Study Compliance Could Face Scrutiny In PDUFA Renewal
FDA says compliance is on par with other postmarketing requirements, but jury is still out on whether public posting of noncompliance letters has been effective tool to ensure timely trial completion.
Pediatric Study Waiver, Deferral Determinations Could Harm Approvals, Firms Tell FDA
Comments on draft guidance say agency’s belated decisions on requests for waivers or deferrals of pediatric studies could lead to “refuse to file” determinations; FDA has missed statutory deadline to promulgate regulations on pediatric study plans.
FDA Calls Out “Egregious” Novartis Petition; Firm Asks Agency To Be Nicer
After the agency reproaches Novartis for what it called a tardy petition seeking to block generic versions of Reclast, the firm offers more information, not in an effort to get FDA to change its mind, but just to change its tone.